Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield - Nevada Lucemyra Prior Aut…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - NevadaPolicy N/A

    Prior authorization requirements for Lucemyra (lofexidine)

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - Nevada policy alerts

    Know when Blue Cross Blue Shield - Nevada releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Form and clinical criteria governing prior authorization requests for Lucemyra (lofexidine) for members served by Anthem Blue Cross and Blue Shield programs in Indiana; applies to prescribing providers submitting PA for covered plans listed on the form.

    Policy Summary
    PayerBlue Cross Blue Shield - Nevada
    PolicyPrior authorization requirements for Lucemyra (lofexidine)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization documenting prior trial and failure of a guideline-accepted alpha-2 adrenergic agonist or provide medical justification; ensure requested quantity ≤16 tablets/day and adheres to the 7-day supply (with subsequent 7-day supply) limit.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    previous trial requiredPrior trial required
    <=16Max tablets/day

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    7+7 days
    Supply limit
    fax PAPA submission

    Coverage Criteria

    Initial Therapy

    Covered when ALL of the following are met:

    Initial prior authorization criteria: (1) Documentation of previous trial and failure of a guideline-accepted alpha-2 adrenergic agonist agent OR medical justification for use over other alpha-2 adrenergic agonists; (2) Requested quantity does not exceed 16 tablets (2.88 mg) per day; (3) Requested claim is within the plan limitation of a seven-day supply with a subsequent seven-day supply for a total of 14 days of therapy every 180 days.

    Confirmation of prior trial can be by claims history or submitted chart documentation.

    The policy covers LUCEMYRA (lofexidine) only when the prior authorization form criteria are met. In addition to the required prior trial/step-therapy and quantity rules, requests must conform to the plan's supply-interval limits and any documentation requirements on the form. Specifically, the requested claim must fall within the plan limitation of an initial 7-day supply with a subsequent 7-day supply (total 14 days) every 180 days, and confirmation of prior therapy must be provided by claims history or submitted chart documentation when applicable.

    Requests that exceed the form’s stated maximum daily tablets or the plan supply limitation require explicit medical justification on the form. The form asks whether the requested quantity does not exceed 16 tablets (2.88 mg) per day and whether the claim is within the plan maximum of a seven-day supply with a subsequent seven-day supply (total 14 days) every 180 days. If either answer is “No,” the provider must supply clinical rationale for continued or greater use; without that documentation the request is not supported by the form.

    Coding & Limits

    Maximum daily tablets — Lucemyra (lofexidine)
    Maximum daily tablets16 tablets (2.88 mg) per day
    Per-day dosing cap descriptionRequested quantity must not exceed 16 tablets (2.88 mg) on any given day
    Policy consequenceRequests exceeding 16 tablets/day are not supported by the form and may be denied
    Plan supply limitation
    Initial supplyInitial 7-day supply
    Subsequent supplySubsequent 7-day supply (total 14 days)
    Supply intervalLimit applies to a 180-day period (maximum total 14 days of therapy every 180 days)

    Provider Actions & Submission

    Prior Authorization

    Prior authorization required with prior-trial and quantity/supply attestations

    Prior authorization is required for LUCEMYRA (lofexidine). The request must document a prior trial and failure of a guideline-accepted alpha-2 adrenergic agonist and attest that the requested daily quantity does not exceed 16 tablets (2.88 mg) and conforms to the plan's 7-day supply limitation with a possible subsequent 7-day supply (total 14 days every 180 days).

    Step Therapy

    Step therapy: prior trial or medical justification required

    Provider must document trial and failure of another guideline-accepted alpha-2 adrenergic agonist agent or supply medical justification explaining why Lucemyra is preferred over other alpha-2 adrenergic agonists.

    Background

    Lucemyra (lofexidine) is an alpha-2 adrenergic agonist used in the management of opioid withdrawal symptoms. The prior authorization form requires documentation of a previous trial and failure of a guideline-accepted alpha-2 adrenergic agonist (with name and dose recorded) or a written medical justification for use over other alpha-2 agents; confirmation of prior trial may be provided by claims history or submitted chart documentation.

    Definitions

    Guideline-accepted alpha-2 adrenergic agonist agent
    DefinitionGuideline-accepted alpha-2 adrenergic agonist agent (example: clonidine)
    Role in policyRequired prior trial and failure of such an agent is a prerequisite for Lucemyra approval unless medical justification is provided
    DocumentationConfirmation of previous trial can be by claims history or submitted chart documentation

    Initial Therapy Criteria

    Initial therapy — Initial authorization requirements

    Initial authorization requirements

    Initial authorization: Provider must document prior trial and failure of a guideline-accepted alpha-2 adrenergic agonist OR provide medical justification for use instead; confirmation of prior trial may be via claims history or submitted chart documentation.

    If no prior trial, medical justification must be provided on the form.

    Quantity limit: Requested quantity must not exceed 16 tablets (2.88 mg) per day.<= 16 tablets (2.88 mg) per day

    Attest on the form that requested daily quantity does not exceed 16 tablets.

    Plan supply limitation: Request must adhere to plan limitation of an initial seven-day supply with a subsequent seven-day supply (for a total of 14 days of therapy) every 180 days.

    Continuation Therapy Criteria

    Continuation therapy limits

    Limits on continuation

    Continuation: Continued use beyond the 14-day total per 180 days requires medical rationale documented on the prior authorization form.> 14 days per 180 days

    Provider must supply clinical rationale on the form if requesting continued use beyond plan limits.

    Step Therapy Requirements

    StepRequirementProvider action / documentation
    1
    Document prior trial and failure of a guideline-accepted alpha-2 adrenergic agonist OR provide medical justification to use Lucemyra instead
    Indicate prior agent name(s) and dose(s) on the form and supply confirmation of prior trial via claims history or submitted chart documentation; if no prior trial, provide medical justification on the form.

    Quantity Limits

    Lucemyra (lofexidine) — quantity limit
    Quantity limit value (max daily tablets)16
    Unit detailtablets (2.88 mg total/day)
    Applies toLucemyra (lofexidine)
    Lucemyra (lofexidine) — supply pattern
    Supply patternInitial 7-day supply followed by a subsequent 7-day supply
    Total allowed per intervalTotal 14 days of therapy every 180 days
    Requirement if exceededIf requesting >14 days in 180 days, provider must supply medical rationale on the form
    Policy Summary
    PayerBlue Cross Blue Shield - Nevada
    PolicyPrior authorization requirements for Lucemyra (lofexidine)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization documenting prior trial and failure of a guideline-accepted alpha-2 adrenergic agonist or provide medical justification; ensure requested quantity ≤16 tablets/day and adheres to the 7-day supply (with subsequent 7-day supply) limit.
    SourceLink
    On This Page
    Coverage CriteriaCoding & LimitsProvider Actions & SubmissionBackgroundDefinitionsInitial Therapy CriteriaContinuation Therapy CriteriaStep Therapy RequirementsQuantity Limits
    Documentation Required

    Document prior trial with claims history or chart documentation

    When prior therapy is claimed, confirmation of the previous trial must be provided by claims history or submitted chart documentation.

    • If prior trial is indicated, list the name(s) and dose(s) of the previous alpha-2 adrenergic agent(s) trialed on the form.
    Billing Rule

    Submit completed form via fax to designated PA center numbers

    Complete the PA form in its entirety and fax it to the Prior Authorization of Benefits Center at 844-864-7860 for retail or 888-209-7838 for medical injectable requests.

    • Ensure the prescribing provider completes all sections; include prescriber signature and return fax/phone as requested.
    • Submit retroactive PA requests separately when dates of service are more than 30 calendar days prior to submission, per form instructions.
    Denial Risk

    Incomplete or missing form sections will cause request return

    The request will be returned if the form is not completed in its entirety or if required sections are missing; the prescribing provider must complete all sections.

    • Mark retroactive PA box and provide dates of service when applicable; omissions related to retroactive submission instructions may cause return of the request.
    Initial 7-day then 7-day (total 14 days) per 180 days

    If requesting continued use beyond 14 days per 180 days, provide medical rationale on the form.